Plasma Rich in Growth Factors for the Treatment of Ocular Surface Diseases
- PMID: 26828610
- DOI: 10.3109/02713683.2015.1104362
Plasma Rich in Growth Factors for the Treatment of Ocular Surface Diseases
Abstract
Purpose: The purpose of this work is to describe and review the technology of plasma rich in growth factors (PRGF), a novel blood derivative product, in the treatment of ocular surface disorders.
Methods: To demonstrate the importance of this technology in the treatment of ocular pathologies, a thorough review of the preclinical and clinical literature results obtained following use of the different therapeutic formulations of PRGF was carried out. A literature search for applications of PGRF plasma in the ophthalmology field was carried out using the PubMed database.
Results: PRGF involves the use of patient's own biologically active proteins, growth factors, and biomaterial scaffolds for therapeutic purposes. This procedural technology is gaining interest in regenerative medicine due to its potential to stimulate and accelerate the tissue healing processes. The versatility and biocompatibility of this technology opens the door to a personalized medicine on ocular tissue regeneration. This review discusses the state of the art of the new treatments and technologies developed to promote ocular surface tissue regeneration. The standardized protocol that has been developed to source eye drops from PRGF technology is also described. The preclinical research, together with the most relevant clinical applications are summarized and discussed.
Conclusions: The preliminary results suggest that the use of PRGF to enhance ocular tissue regeneration is safe and efficient.
Keywords: Cornea; PRGF; PRP; ocular surface; platelet-rich plasma.
Similar articles
-
Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies.Acta Ophthalmol. 2015 Dec;93(8):e605-14. doi: 10.1111/aos.12710. Epub 2015 Apr 2. Acta Ophthalmol. 2015. PMID: 25832910 Review.
-
Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop.Exp Eye Res. 2014 Feb;119:27-34. doi: 10.1016/j.exer.2013.12.005. Epub 2013 Dec 15. Exp Eye Res. 2014. PMID: 24345372
-
Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts.Exp Eye Res. 2015 Jun;135:118-26. doi: 10.1016/j.exer.2015.02.016. Epub 2015 Feb 21. Exp Eye Res. 2015. PMID: 25708868
-
Beneficial Effects of Plasma Rich in Growth Factors (PRGF) Versus Autologous Serum and Topical Insulin in Ocular Surface Cells.Curr Eye Res. 2023 May;48(5):456-464. doi: 10.1080/02713683.2023.2173237. Epub 2023 Feb 7. Curr Eye Res. 2023. PMID: 36695530
-
Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus.Expert Opin Biol Ther. 2022 Jan;22(1):31-45. doi: 10.1080/14712598.2021.1945030. Epub 2021 Jul 19. Expert Opin Biol Ther. 2022. PMID: 34275392 Review.
Cited by
-
Biological and Adhesive Properties of an Autologous Protein-Based Fibrin Sealant for Ophthalmological Applications.Transl Vis Sci Technol. 2023 Nov 1;12(11):32. doi: 10.1167/tvst.12.11.32. Transl Vis Sci Technol. 2023. PMID: 38015168 Free PMC article.
-
Differential profile of protein expression on human keratocytes treated with autologous serum and plasma rich in growth factors (PRGF).PLoS One. 2018 Oct 12;13(10):e0205073. doi: 10.1371/journal.pone.0205073. eCollection 2018. PLoS One. 2018. PMID: 30312303 Free PMC article.
-
Use of plasma rich in growth factors (PRGF-Endoret®) fibrin membrane to cover corneal dellen.Rom J Ophthalmol. 2021 Jul-Sep;65(3):293-295. doi: 10.22336/rjo.2021.60. Rom J Ophthalmol. 2021. PMID: 35036656 Free PMC article.
-
Nanotechnology in regenerative ophthalmology.Adv Drug Deliv Rev. 2019 Aug;148:290-307. doi: 10.1016/j.addr.2019.10.006. Epub 2019 Nov 7. Adv Drug Deliv Rev. 2019. PMID: 31707052 Free PMC article. Review.
-
Tissue Engineering and Ophthalmology.Turk J Ophthalmol. 2024 Jun 28;54(3):159-169. doi: 10.4274/tjo.galenos.2024.49779. Turk J Ophthalmol. 2024. PMID: 38940358 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials